[{"notes_id":"1_1649","category":"1","subcategory":"1","title":"Myocardial infarction: secondary prevention","body":"NICE produced guidelines on the management of patients following a myocardial infarction (MI) in 2013. Some key points are listed below<br \/><br \/><span class=\"concept\" data-cid=\"11545\">All patients should be offered the following drugs<\/span>:<br \/><ul><li>dual antiplatelet therapy (aspirin plus a second antiplatelet agent)<\/li><li>ACE inhibitor <\/li><li>beta-blocker<\/li><li>statin<\/li><\/ul><br \/>Some selected lifestyle points:<br \/><ul><li>diet: advise a Mediterranean style diet, switch butter and cheese for plant oil based products. Do not recommend omega-3 supplements or eating oily fish<\/li><li>exercise: advise 20-30 mins a day until patients are 'slightly breathless'<\/li><li><span class=\"concept\" data-cid=\"372\">sexual activity may resume 4 weeks after an uncomplicated MI<\/span>. Reassure patients that sex does not increase their likelihood of a further MI. PDE5 inhibitors (e.g, sildenafil) may be used 6 months after a MI. They should however be avoided in patient prescribed either nitrates or nicorandil<\/li><\/ul><br \/>Most patients who've had an acute coronary syndrome are now given dual antiplatelet therapy (DAPT). Clopidogrel was previously the second antiplatelet of choice. Now ticagrelor and prasugrel (also ADP-receptor inhibitors) are more widely used. NICE now recommend:<br \/><ul><li>post acute coronary syndrome (medically managed): add ticagrelor to aspirin, stop ticagrelor after 12 months<\/li><li>post percutaneous coronary intervention: add prasugrel or ticagrelor to aspirin, stop the second antiplatelet after 12 months<\/li><li>this 12 month period may be altered for people at a high-risk of bleeding or those who at high-risk of further ischaemic events<\/li><\/ul><br \/>Aldosterone antagonists<br \/><ul><li><span class=\"concept\" data-cid=\"9699\">patients who have had an acute MI and who have symptoms and\/or signs of heart failure and left ventricular systolic dysfunction, treatment with an aldosterone antagonist<\/span> licensed for post-MI treatment (e.g. eplerenone) should be initiated within 3-14 days of the MI, preferably after ACE inhibitor therapy<\/li><\/ul>","notes_hash":"7b03b88e6ebde825d0c2d48c58011c5d","knowledge_graph_node_id_link":0,"links":"<table style='width:100%'><tr><td>European Society of Cardiology<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_925\" data-linkid=\"925\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_925\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">6<\/span><button type=\"button\" style=\"\" id=\"link_dislike_925\" data-linkid=\"925\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_925\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">14<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/academic.oup.com\/eurheartj\/article\/39\/2\/119\/4095042\">2017 STEMI guidelines<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_350\" data-linkid=\"350\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_350\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">13<\/span><button type=\"button\" style=\"\" id=\"link_dislike_350\" data-linkid=\"350\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_350\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">7<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng185\">2020 Acute coronary syndromes guidelines<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":{"11545":{"concept_text":"Following an ACS, all patients should be offered:\n   - dual antiplatelet therapy (aspirin plus a second antiplatelet agent)\n   - ACE inhibitor \n   - beta-blocker\n   - statin","concept_percentile":"71"}},"category_name":"Cardiovascular","subcategory_name":"Cardiology","comment_count":6},"",[]]